The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | A pilot study investigating a shorter duration of isatuximab infusion in patients with myeloma
Enrique Ocio, MD, PhD, Marquis of Valdecilla University Hospital, Santander, Spain, comments on a pilot study within a larger Phase Ib study (NCT02513186) of isatuximab, bortezomib, lenalidomide, and dexamethasone (Isa-VRd) followed by Isa-Rd maintenance in patients with newly diagnosed multiple myeloma (MM) not eligible for or with no immediate intent for transplant. The pilot study investigated the feasibility of administering isatuximab in a 30-minute infusion. This approach was found to have favorable tolerability and safety, and Dr Ocio notes that this method is already being implemented in clinical practice. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (AI-generated)
Another advantage for isatuximab is that, as you know, isatuximab is now given IV, but we have now done in this study a pilot trial in which we are using isatuximab in a 30-minute infusion, so a much shorter infusion of treatment. These are patients that were, presumably around 40 patients, that were into the maintenance phase of the trial Isa-VRd and then with Isa-Rd and they receive Isatuximab with a much faster infusion in 25 milliliters and they have escalated to reduce the dose...
Another advantage for isatuximab is that, as you know, isatuximab is now given IV, but we have now done in this study a pilot trial in which we are using isatuximab in a 30-minute infusion, so a much shorter infusion of treatment. These are patients that were, presumably around 40 patients, that were into the maintenance phase of the trial Isa-VRd and then with Isa-Rd and they receive Isatuximab with a much faster infusion in 25 milliliters and they have escalated to reduce the dose. Now the patients are receiving isatuximab in 30 minutes. The tolerability was excellent. Only one patient had an infusion reaction, that was a patient that had been out of treatment for many months but then when we restarted he had an infusion reaction, but all of them had very good data, very good safety, and very short, as I said, 30-minute infusion with isatuximab. And I think probably this is the way to go. And this is what we are, in fact, we are doing in our patients in the clinical practice. After some doses in which they receive the current dose, the approved dose, then they move to the fast infusion of this drug.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
